NASDAQ:SVRA Savara (SVRA) Stock Forecast, Price & News $3.70 -0.04 (-1.07%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$3.65▼$3.7750-Day Range$3.24▼$3.8852-Week Range$1.08▼$4.21Volume494,655 shsAverage Volume425,024 shsMarket Capitalization$500.13 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Savara MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside35.1% Upside$5.00 Price TargetShort InterestHealthy2.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$1.02 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector648th out of 964 stocksPharmaceutical Preparations Industry288th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingSavara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Savara has a forecasted upside of 35.1% from its current price of $3.70.Amount of Analyst CoverageSavara has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.68% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Savara has recently increased by 1.35%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SVRA. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Savara this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SVRA on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows4 people have added Savara to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Savara insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,019,044.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.58% of the stock of Savara is held by insiders.Percentage Held by Institutions97.28% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Savara are expected to remain at ($0.29) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Savara (NASDAQ:SVRA) StockSavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More SVRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SVRA Stock News HeadlinesSeptember 13, 2023 | seekingalpha.comMolgramostim: Savara's Single Shot At SuccessSeptember 11, 2023 | finance.yahoo.comSavara Inc.'s (NASDAQ:SVRA) Path To ProfitabilitySeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 5, 2023 | finance.yahoo.comSavara to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 31, 2023 | msn.comSavara (SVRA) Price Target Increased by 17.02% to 5.61August 14, 2023 | msn.comHC Wainwright & Co. Maintains Savara (SVRA) Buy RecommendationAugust 11, 2023 | finance.yahoo.comSavara Reports Second Quarter Financial Results and Provides Business UpdateJuly 21, 2023 | benzinga.com10% Owner of Savara Makes $999K BuySeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJuly 20, 2023 | benzinga.comSavara Recent Insider ActivityJuly 20, 2023 | benzinga.com999K Reasons To Be Bullish On Savara StockJuly 16, 2023 | seekingalpha.comSavara: A Speculative PlayJuly 13, 2023 | seekingalpha.comSavara prices $80M common stock and pre-funded warrants offeringJuly 13, 2023 | marketwatch.comSavara Shares Near 52-Week High After $80M Offering PricesJuly 13, 2023 | marketwatch.comSavara Prices Share Offering at $3 a ShareJuly 13, 2023 | finance.yahoo.comSavara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsJune 26, 2023 | msn.comSavara joins Russell 3000June 26, 2023 | finance.yahoo.comSavara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)June 13, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Evolent Health (EVH), Savara (SVRA)June 2, 2023 | finance.yahoo.comSavara to Present at the Jefferies Healthcare ConferenceMay 28, 2023 | finance.yahoo.comIndependent Director of Savara David Ramsay Buys 4.8% More SharesMay 28, 2023 | finance.yahoo.comIndependent Director of Savara David Ramsay Buys 4.8% More Shares \May 17, 2023 | msn.comHC Wainwright & Co. Reiterates Savara (SVRA) Buy RecommendationMay 17, 2023 | markets.businessinsider.comSavara (SVRA) Gets a Buy from H.C. WainwrightMay 16, 2023 | msn.comWhy Shares of Savara Jumped on TuesdayMay 16, 2023 | msn.comSavara rises as Jefferies upgrades citing 100% upsideMay 15, 2023 | finance.yahoo.comSavara Reports First Quarter Financial Results and Provides Business UpdateSee More Headlines Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Email Address SVRA Company Calendar Last Earnings8/10/2023Today9/26/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+33.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,150,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.62% Return on Assets-31.81% Debt Debt-to-Equity Ratio0.30 Current Ratio18.33 Quick Ratio18.33 Sales & Book Value Annual Sales$260,000.00 Price / Sales1,944.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book3.94Miscellaneous Outstanding Shares135,170,000Free Float128,982,000Market Cap$505.54 million OptionableOptionable Beta0.89 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesRobert N. Neville (Age 51)Chairman of the Board, Chief Executive Officer Taneli Jouhikainen (Age 51)President, Chief Operating Officer David L. Lowrance (Age 50)Chief Financial Officer Nevan C. Elam (Age 49)Independent Director Richard J. Hawkins (Age 68)Independent Director Joseph S. McCracken Ph.D. (Age 64)Independent Director Matthew Pauls J.D. (Age 46)Independent Director Yuri Pikover (Age 56)Independent Director More ExecutivesKey CompetitorsHarrow HealthNASDAQ:HROWEvolusNASDAQ:EOLSOlema PharmaceuticalsNASDAQ:OLMAAclaris TherapeuticsNASDAQ:ACRSPhibro Animal HealthNASDAQ:PAHCView All CompetitorsInsiders & InstitutionsBarclays PLCSold 9,338 shares on 9/21/2023Ownership: 0.011%California State Teachers Retirement SystemBought 25,362 shares on 8/21/2023Ownership: 0.019%Nuveen Asset Management LLCBought 144,335 shares on 8/16/2023Ownership: 0.107%Alliancebernstein L.P.Bought 11,940 shares on 8/15/2023Ownership: 0.009%Royal Bank of CanadaBought 7,751 shares on 8/15/2023Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions SVRA Stock - Frequently Asked Questions Should I buy or sell Savara stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SVRA shares. View SVRA analyst ratings or view top-rated stocks. What is Savara's stock price forecast for 2023? 2 analysts have issued 1 year target prices for Savara's stock. Their SVRA share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price. View analysts price targets for SVRA or view top-rated stocks among Wall Street analysts. How have SVRA shares performed in 2023? Savara's stock was trading at $1.55 on January 1st, 2023. Since then, SVRA stock has increased by 141.3% and is now trading at $3.74. View the best growth stocks for 2023 here. When is Savara's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our SVRA earnings forecast. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) issued its earnings results on Thursday, August, 10th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP). What is Savara's stock symbol? Savara trades on the NASDAQ under the ticker symbol "SVRA." Who are Savara's major shareholders? Savara's stock is owned by a variety of institutional and retail investors. Top institutional investors include Caxton Corp (3.68%), BlackRock Inc. (4.29%), Jennison Associates LLC (2.34%), Geode Capital Management LLC (1.61%), State Street Corp (0.99%) and Northern Trust Corp (0.55%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken, Matthew Pauls, Raymond Dennis Pratt and Rick Yang. View institutional ownership trends. How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Savara's stock price today? One share of SVRA stock can currently be purchased for approximately $3.74. How much money does Savara make? Savara (NASDAQ:SVRA) has a market capitalization of $505.54 million and generates $260,000.00 in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. How can I contact Savara? Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876. This page (NASDAQ:SVRA) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.